A Study of LY3981314 in Participants With Autoimmune Hepatitis
An Open Label, Single-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effect of LY3981314 in Patients With Autoimmune Hepatitis
The purpose of the study is to assess if a single dose of LY3981314 is safe in participants with autoimmune hepatitis. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body
The study will last about 30 weeks.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: LillyTrials@Lilly.com
Study Contact Backup
- Name: Physicians interested in becoming principal investigators please contact
- Email: clinical_inquiry_hub@lilly.com
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Health
-
Principal Investigator:
- Craig Lammert
-
Contact:
- Phone Number: 317-278-9292
-
-
Texas
-
Dallas, Texas, United States, 75203
- Methodist Dallas Medical Center
-
Principal Investigator:
- Parvez Mantry
-
Contact:
- Phone Number: 214-947-4450
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Have a confirmed diagnosis of autoimmune hepatitis (AIH) for greater than or equal to (≥) 6 months according to American Association for the Study of Liver Diseases diagnostic criteria (Appendix 8, Section 10.8)
-
Have alanine aminotransferase (ALT) greater than (>) 1.5x upper limit of normal (ULN) to less than (<) 5x ULN
-
Have elevated soluble FAS (sFAS) based on Sponsor predetermined threshold
-
Be on a stable immunosuppressive medication regimen for AIH with no dose changes or weaning of treatment for ≥8 weeks prior to screening, and no anticipated medication adjustments until after the post-treatment liver biopsy at Day 29. The following medications are permitted for the management of AIH:
- Azathioprine
- 6-Mercaptopurine
- Inhibitors of inosine monophosphate dehydrogenase (mycophenolate mofetil, mycophenolate sodium, mycophenolic acid)
- Tacrolimus
- Cyclosporine
- Corticosteroids at a dose equivalent to less than or equal to (≤) 10 mg of prednisone per day
Exclusion Criteria:
-
Have clinical, laboratory, histological, or imaging evidence of cirrhosis
-
Have a controlled attenuation parameter (CAP) score >300 decibel-milliwatt (dB/m) as measured by transient elastography
-
Have clinical evidence of hepatic decompensation as defined by the presence of any of the following abnormalities
- international normalized ratio >1.3
- history of esophageal varices, ascites or hepatic encephalopathy
-
Have or had other forms of chronic liver disease per Medical History:
- alcoholic liver disease
- hepatitis B
- hepatitis C
- history of primary biliary cholangitis or primary sclerosing cholangitis
- history of celiac disease, or other autoimmune disorders including immune-checkpoint related hepatitis associated with elevated aminotransferases
- uncontrolled thyroid disease
- current drug-induced liver disease based on typical exposure and history
- metabolic dysfunction associated steatohepatitis, Wilson's disease, hemochromatosis, alpha-1-antitrypsin deficiency, or cystic fibrosis-related liver disease
- suspected or proven liver cancer
- any other physician confirmed liver disease other than AIH
-
Have any medical condition that, in the opinion of the investigator, may increase the risk of complications related to liver biopsy (for example, a known coagulopathy, inherited disorders of hemostasis, sickle cell disease, amyloidosis)
-
Have any of the following laboratory abnormalities at screening:
-
Platelet count <150,000/cubic millimeter (mm³)
-
Hemoglobin
- <10 grams per deciliter (g/dL) for individuals assigned female at birth (AFAB)
- <11 g/dL for individuals assigned male at birth (AMAB)
-
Absolute neutrophil count <1000/mm³
-
Transferrin saturation >50 percentage (%) (except when it has been demonstrated that a diagnosis of hemochromatosis has been excluded by genetic testing or when a previous liver biopsy has demonstrated no evidence of iron overload.)
-
Total bilirubin > ULN unless known Gilbert's syndrome per Medical History.
- Gilbert's syndrome participant must have normal direct bilirubin; if diagnosis of Gilbert's cannot be confirmed by medical records, participant may not participate in the study
-
Have renal impairment measured as estimated glomerular filtration rate<60 milliliters per minute (mL/min)/1.73 square meter (m²), calculated using the Chronic Kidney Disease Epidemiology Collaboration Creatinine Equation (2021 version), as determined by the local laboratory during screening
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: LY3981314
LY3981314 administered subcutaneously (SC) |
Administered SC |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: Baseline up to Approximately Week 25
|
Baseline up to Approximately Week 25
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetics (PK): Plasma Concentrations of LY3981314
Time Frame: Baseline Up to Approximately Week 25
|
Baseline Up to Approximately Week 25
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 27811
- J6H-MC-KXAB (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.